NASDAQ:URGN - Urogen Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.71 -0.96 (-2.30 %)
(As of 02/22/2019 06:00 AM ET)
Previous Close$41.67
Today's Range$40.09 - $41.80
52-Week Range$36.95 - $69.57
Volume102,969 shs
Average Volume356,125 shs
Market Capitalization$559.76 million
P/E Ratio-19.02
Dividend YieldN/A
Beta1.6
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.16 million
Book Value$4.98 per share

Profitability

Net Income$-20,000,000.00
Net Margins-4,296.08%

Miscellaneous

Employees46
Market Cap$559.76 million
Next Earnings Date3/21/2019 (Estimated)
OptionableOptionable

Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) posted its earnings results on Tuesday, August, 14th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.25. The company earned $0.36 million during the quarter. Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 61.06%. View Urogen Pharma's Earnings History.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Urogen Pharma.

What price target have analysts set for URGN?

8 Wall Street analysts have issued 12 month price objectives for Urogen Pharma's shares. Their predictions range from $65.00 to $82.00. On average, they anticipate Urogen Pharma's share price to reach $73.80 in the next year. This suggests a possible upside of 81.3% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

What is the consensus analysts' recommendation for Urogen Pharma?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

Has Urogen Pharma been receiving favorable news coverage?

Press coverage about URGN stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Urogen Pharma earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the next few days.

Are investors shorting Urogen Pharma?

Urogen Pharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,033,334 shares, an increase of 34.1% from the January 15th total of 770,675 shares. Based on an average daily trading volume, of 533,914 shares, the days-to-cover ratio is presently 1.9 days. Currently, 6.5% of the company's shares are sold short. View Urogen Pharma's Current Options Chain.

Who are some of Urogen Pharma's key competitors?

What other stocks do shareholders of Urogen Pharma own?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are Urogen Pharma's major shareholders?

Urogen Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (2.90%), BlackRock Inc. (2.18%), Delek Group Ltd. (1.19%), Millennium Management LLC (0.80%), Shikiar Asset Management Inc. (0.54%) and Alps Advisors Inc. (0.27%). View Institutional Ownership Trends for Urogen Pharma.

Which institutional investors are selling Urogen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Oconnor LLC, UBS Oconnor LLC, Shikiar Asset Management Inc., Mackenzie Financial Corp, California Public Employees Retirement System, Harel Insurance Investments & Financial Services Ltd. and Two Sigma Advisers LP. View Insider Buying and Selling for Urogen Pharma.

Which institutional investors are buying Urogen Pharma stock?

URGN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Clal Insurance Enterprises Holdings Ltd, Delek Group Ltd., Altshuler Shaham Ltd, Assenagon Asset Management S.A., Alps Advisors Inc., Northern Trust Corp and ETF Managers Group LLC. View Insider Buying and Selling for Urogen Pharma.

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $40.71.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $559.76 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 46 workers across the globe.

What is Urogen Pharma's official website?

The official website for Urogen Pharma is http://www.urogen.com.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 9 Ha'Ta'asiya Street, Ra'anana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]


MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel